Promimic (PRO) Q4 2024 earnings summary

Executive summary

• Achieved record net sales of 12.6 MSEK in Q4 2024, up 24% year-over-year, with 41% growth in license and royalty revenues.

• Full-year net sales reached 44.0 MSEK, a 19% increase, marking an all-time high.

• Over 2 million implants with Promimic's technology now in clinical use, with the second million achieved in just two years.

• Significant progress in infection prevention research, showing up to 46% reduction in bacteria on HAnano Surface.

Financial highlights

• Q4 2024 net sales: 12.6 MSEK (10.2), operating income: -1.1 MSEK (-3.4), net result: -5.0 MSEK (-3.5), EPS: -0.26 SEK (-0.19).

• Full-year 2024 net sales: 44.0 MSEK (37.1), operating income: -8.3 MSEK (-9.1), net result: -12.6 MSEK (-9.2), EPS: -0.67 SEK (-0.50).

• Cash flow for the year: -15.2 MSEK (-8.2); cash at year-end: 35.8 MSEK (50.3).

• Royalty and license revenues for the rolling four quarters: 19.7 MSEK (14.9), up 33%.

• EBITDA for Q4: 178 TSEK (-2,126); for the year: -3,245 TSEK (-5,000).

Outlook and guidance

• Management expects continued growth in established and new markets, with new application areas and market segments to be added in 2025.

• Financial target: reach 100 MSEK in sales and EBITDA margin above 40% by 2026.